EA Phenomic

Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies

Retrieved on: 
Thursday, November 30, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Research, Artificial intelligence, Machine learning, Neoplasm, Drug discovery, Cancer, Antibody, EA Phenomic, Astellas Pharma

Phenomic AI Inc. (“Phenomic”), a biotech company developing therapies for stroma-rich tumors using its scTx® single cell transcriptomics platform, has entered into a strategic research collaboration with Astellas Pharma Inc., “Astellas” through Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas).

Key Points: 
  • Phenomic AI Inc. (“Phenomic”), a biotech company developing therapies for stroma-rich tumors using its scTx® single cell transcriptomics platform, has entered into a strategic research collaboration with Astellas Pharma Inc., “Astellas” through Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas).
  • For this collaboration, Phenomic and Astellas will explore the ability of antibodies, developed by Phenomic and directed at a novel target of the tumor stroma identified with Phenomic’s scTx platform, to enhance cell therapy approaches for the treatment of solid tumors.
  • Phenomic AI (“Phenomic”) is a biopharmaceutical company dedicated to overcoming the tumor stroma, a complex barrier that drives poor outcomes in the majority of solid tumors.
  • Through its unique platform, Phenomic is developing a robust portfolio of potential first-in-class drug candidates to treat challenging stroma-rich solid cancers.

Phenomic Enters Strategic Collaboration with Boehringer Ingelheim to Discover Novel Targets for Stroma-Rich Cancer Therapies

Retrieved on: 
Wednesday, November 29, 2023
Research, Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Other Science, Boehringer Ingelheim, Tissue, Database, Patient, Algorithm, Artificial intelligence, USD, Machine learning, Therapy, Drug discovery, Cancer, Partnership, Metastasis, Biology, RNA, Pharmaceutical industry, EA Phenomic

Phenomic AI (“Phenomic”) today announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers.

Key Points: 
  • Phenomic AI (“Phenomic”) today announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers.
  • We are excited to be working with Boehringer Ingelheim, a global leader with expertise in delivering breakthrough medicines for cancer patients,” stated Girish Aakalu, Ph.D., CEO of Phenomic.
  • Under the agreement, Boehringer Ingelheim has the option to license targets discovered and functionally validated by Phenomic as a basis for novel cancer therapeutics.
  • Boehringer Ingelheim will also be responsible for all non-clinical and clinical development, as well as commercialization of associated cancer therapies.

Latest Updates of Viva's Portfolio Companies

Retrieved on: 
Monday, December 4, 2023
JAK1, NMPA, Patient, American College of Rheumatology, Bayer, SUA, Neoplasm, Cataract, Therapy, URAT1, MBA, Cancer, Health care, Inflammation, Fabry disease, Safety, Toxicity, IND, SHP2, USD, Strong, Letter, Woman, EA Phenomic, Pharmacokinetics, VBI, HER2, MPM, Antibody, GCS, GEJ, Boehringer, Research, Plasma, Boehringer Ingelheim, Clinical trial, Investment, MaRS Discovery District, FDA, American College, Phase II, Clostridial necrotizing enteritis, Selective, MPH, ACR, EGFR, Pharmaceutical industry, Astellas Pharma, Phase, Deka, Facet joint arthrosis

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--On Nov. 29th, Phenomic AI ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales.

Key Points: 
  • HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva's portfolio companies have new updates.
  • Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones.